Skip to main content

Advertisement

SpringerLink
Log in

Triple therapy in refractory detrusor overactivity: a preliminary study

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate in a prospective study the impact of the “three-drug therapy” (antimuscarinic, alpha-blocker and tricyclic antidepressants) on the treatment of refractory detrusor overactivity (DO).

Methods

Data from 27 consented patients with refractory DO were available for study. They were asked to complete a daily urinary chart and underwent urodynamic evaluation (UD) before and 60 days after treatment. Response to treatment was considered the presence of one or less involuntary detrusor contractions (IDC) on post-treatment UD. Statistical analysis was performed with Fisher and Mann–Whitney tests, besides Spearman’s correlation. P values <0.05 were considered significant.

Results

The mean follow-up was 15 months. The comparison of the daily urinary chart before and after treatment showed significant increase on bladder capacity and decreases on urgency, urge-incontinence and frequency. Objective data from UD showed that the mean maximum bladder capacity (MBC) ranged from 200 to 300 mL (P < 0.001) with treatment. The same trend was observed with the other UD variables. When compared to baseline, the questionnaire OAB-v8 showed significant improvement (P < 0.01). Main side effects comprised dry mouth and constipation (40%), with average scores of 5.16 and 3.08, respectively (visual scale from 0 to 10).

Conclusions

Triple therapy may be an effective, easily employed and well-tolerated option to refractory DO treatment. More studies are necessary to achieve more consistent data on the matter.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hashim H, Abrams P (2004) Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 64:1643–1656

    Article  CAS  PubMed  Google Scholar 

  2. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987–1006

    CAS  PubMed  Google Scholar 

  3. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37–49

    Article  PubMed  Google Scholar 

  4. Brown JS, McGhan WF, Chokroverty S (2000) Comorbidities associated with overactive bladder. Am J Manag Care 6:574–579

    Google Scholar 

  5. Kilic N, Balkan E, Akgoz S et al (2006) Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urol 13:105–108

    Article  CAS  PubMed  Google Scholar 

  6. Wein AJ (1998) Pharmacologic options for the overactive bladder. Urology 51:43–47

    Article  CAS  PubMed  Google Scholar 

  7. Hawthorn MH, Chapple CR, Cock M et al (2000) Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 129:416–419

    Article  CAS  PubMed  Google Scholar 

  8. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder afferent pathways. Urology 65:238–242

    Article  PubMed  Google Scholar 

  9. Finney SM, Andersson KE, Gillespie JI et al (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98:503–507

    Article  CAS  PubMed  Google Scholar 

  10. Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol 43:1–5

    Article  CAS  PubMed  Google Scholar 

  11. Kim Y, Yoshimura N, Masuda H et al (2006) Intravesical installation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 97:400–403

    Article  CAS  PubMed  Google Scholar 

  12. MacDiarmid SA (2007) Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? BJU Int 99:8–12

    Article  CAS  PubMed  Google Scholar 

  13. Dmochowski R (2002) Interventions for detrusor overactivity: the case for multimodal therapy. Rev Urol 4:19–27

    Google Scholar 

  14. Ruggieri MR Sr, Braverman AS, Pontari MA (2005) Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 174:1743–1748

    Article  CAS  PubMed  Google Scholar 

  15. Salvatore S, Soligo M, Proietti F et al (2005) Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. Eur J Obstet Gynecol Reprod Biol 120:129–133

    Article  CAS  PubMed  Google Scholar 

  16. Chen Q, Takahashi S, Zhong S et al (2005) Function of the lower urinary tract in mice lacking a1d-adrenoceptor. J Urol 174:370–374

    Article  CAS  PubMed  Google Scholar 

  17. Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49:651–659

    Article  PubMed  Google Scholar 

  18. Penttila J, Syvalahti E, Hinkka S et al (2001) The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 154:343–349

    Article  CAS  Google Scholar 

  19. Andersson KE (2000) Treatment of overactive bladder: other drug mechanisms. Urology 55:51–57

    Article  CAS  PubMed  Google Scholar 

  20. Sacco E, Pinto F, Bassi P (2008) Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J 19:583–598

    Article  Google Scholar 

  21. Miller KL, Dubeau CE, Bergmann M, Griffiths DJ, Resnick NM (2002) Quest for a detrusor overactivity index. J Urol 167:578–585

    Article  CAS  PubMed  Google Scholar 

  22. Sellers DJ, McKay N (2007) Developments in the pharmacotherapy of the overactive bladder. Curr Opin Urol 17:223–230

    Article  PubMed  Google Scholar 

  23. Witte LPW, Mulder WMC, de la Rosette JJMCH, Miche MC (2009) Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 19:13–19

    Article  PubMed  Google Scholar 

  24. Andersson KE (2006) Treatment-resistant detrusor overactivity—underlying pharmacology and potential mechanisms. Int J Clin Pract 60:8–16

    Article  Google Scholar 

  25. Novara G, Galfano A, Ficarra V et al (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 50:675–683

    Article  CAS  PubMed  Google Scholar 

  26. Horstmann M, Schaefer T, Aguilar Y et al (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25:441–445

    Article  CAS  PubMed  Google Scholar 

  27. Menarini M, Del Popolo G, Di Benedetto P et al (2006) Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 44:623–632

    CAS  PubMed  Google Scholar 

  28. Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert K (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 53:1021–1028

    Article  CAS  PubMed  Google Scholar 

  29. Payne CK, Kelleher C (2007) Redefining response in overactive bladder syndrome. BJU Int 99:101–106

    Article  CAS  PubMed  Google Scholar 

  30. Kobelt G, Borgstrom F, Mattiasson A (2003) Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 91:190–195

    Article  CAS  PubMed  Google Scholar 

  31. Samuelsson E, Victor A, Tibblin G (1997) A population study of urinary incontinence and nocturia among women aged 20–59 years. Prevalence, well being and wish for treatment. Acta Obstet Gynecol Scand 76:74–80

    Article  CAS  PubMed  Google Scholar 

  32. Irwin DE, Milsom I, Kopp Z et al (2006) Impact of overactive bladder symptoms on employment, social interactions and emotional well being in six European countries. BJU Int 97:96–100

    Article  PubMed  Google Scholar 

  33. Fultz N, Girts T, Kinchen K et al (2005) Prevalence, management and impact of urinary incontinence in the workplace. Occup Med 55:552–557

    Article  Google Scholar 

  34. Hashim H, Abrams P (2007) Overactive bladder: an update. Curr Opin Urol 17:231–236

    Article  PubMed  Google Scholar 

  35. Brown JS, Vittinghoff E, Wyman JF et al (2000) Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 48:721–725

    CAS  PubMed  Google Scholar 

  36. Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766

    Article  CAS  PubMed  Google Scholar 

  37. Reeves P, Irwin D, Kelleher C et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50:1050–1057

    Article  PubMed  Google Scholar 

  38. Serels S, Stein M (1998) Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn 17:31–36

    Article  CAS  PubMed  Google Scholar 

  39. Staskin DR, MacDiarmid SA (2006) Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 119:9–15

    Article  PubMed  Google Scholar 

  40. Andersson KE, Chapple CR (2001) Oxibutinin and the overactive bladder. World J Urol 19:319–323

    Article  CAS  PubMed  Google Scholar 

  41. Serrano Brambila EA, Quiroga Avila RG, Lorenzo Monterrubio JL et al (2000) Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women. Ginecol Obstet Mex 68:174–181

    CAS  PubMed  Google Scholar 

  42. Brostrom S, Hallas J (2009) Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. doi: 10.1007/s00228-008-0600-9

  43. Witte LPW, Mulder WMC, de la Rosette JJMCH, Miche MC (2009) Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 19:13–19

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Urology, University of Campinas, UNICAMP, Campinas, SP, 13073-090, Brazil

    Ricardo Natalin, Leonardo Oliveira Reis, Cristiano Alpendre, Lia Y. Ikari, Alessandro Prudente & Carlos A. L. D’Ancona

  2. R. Votorantim, 51, ap. 43, Campinas, SP, 13073-090, Brazil

    Leonardo Oliveira Reis

Authors
  1. Ricardo Natalin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonardo Oliveira Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristiano Alpendre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lia Y. Ikari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandro Prudente
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlos A. L. D’Ancona
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonardo Oliveira Reis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Natalin, R., Reis, L.O., Alpendre, C. et al. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol 28, 79–85 (2010). https://doi.org/10.1007/s00345-009-0400-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-009-0400-6

Keywords

Search

Navigation